Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$65.34 USD
+0.54 (0.83%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $65.32 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Income Statements
Fiscal Year end for Cytokinetics, Incorporated falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 8 | 95 | 70 | 56 | 27 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 8 | 95 | 70 | 56 | 27 |
Selling & Adminstrative & Depr. & Amort Expenses | 504 | 419 | 257 | 150 | 126 |
Income After Depreciation & Amortization | -496 | -324 | -186 | -94 | -99 |
Non-Operating Income | 28 | -14 | 0 | 5 | 5 |
Interest Expense | 58 | 51 | 29 | 39 | 27 |
Pretax Income | -526 | -389 | -215 | -127 | -122 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -526 | -389 | -215 | -127 | -122 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -526 | -389 | -215 | -127 | -122 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -484 | -318 | -184 | -92 | -98 |
Depreciation & Amortization (Cash Flow) | 12 | 6 | 2 | 2 | 1 |
Income After Depreciation & Amortization | -496 | -324 | -186 | -94 | -99 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 96.52 | 89.83 | 76.89 | 64.52 | 57.58 |
Diluted EPS Before Non-Recurring Items | -5.45 | -4.06 | -2.80 | -1.97 | -2.11 |
Diluted Net EPS (GAAP) | -5.45 | -4.33 | -2.80 | -1.97 | -2.11 |
Fiscal Year end for Cytokinetics, Incorporated falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 1.67 | 0.38 | 0.87 | 4.61 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 1.67 | 0.38 | 0.87 | 4.61 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 129.09 | 122.64 | 122.91 | 129.09 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -127.42 | -122.26 | -122.04 | -124.48 |
Non-Operating Income | NA | 7.59 | 6.84 | 6.78 | 6.43 |
Interest Expense | NA | 17.06 | 14.00 | 13.37 | 13.24 |
Pretax Income | NA | -136.90 | -129.42 | -128.64 | -131.29 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -136.90 | -129.42 | -128.64 | -131.29 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -136.90 | -129.42 | -128.64 | -131.29 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 99.07 | 96.07 | 95.76 | 95.16 |
Diluted EPS Before Non-Recurring Items | NA | -1.38 | -1.35 | -1.34 | -1.38 |
Diluted Net EPS (GAAP) | NA | -1.38 | -1.35 | -1.34 | -1.38 |